Effect of Simvastatin on Improvement of Follicular Apoptosis through Interaction with Tumor Necrosis Factor-α and Changes in Anti-Mullerian Hormone Levels in Female Rats with Polycystic Ovary Syndrome
Resumo
Polycystic ovary syndrome (PCOS) is the most frequent female endocrine disorder affecting about 5%–10% of women and causing infertility due to dysfunctional follicular maturation and ovulation. Objective: Simvastatin has an anti-inflammatory impact by trace on leukocytes and cytokines, which inhibit cellular proliferation, reduce androgen production and leads to apoptosis creation in antral follicle.Methods: The total of 60 wistar female rats were divided into three experimental groups. The experimental groups were injected each evening with DHEA (6 mg/100 g body weight/0.2 ml sesame oil) for 20 days. Then were divided into two groups (comparison group (PCOS) and treatment group (PCT)). The treatment group received of simvastatin (10 mg/kg body weight 1.5 ml of saline) for 4 weeks. The investigation of ovarian tissue was done with immunohistochemical and histopathologic methods. Results: Simvastatin drug led to a significant decrease in the serum level of AMH in the PCT compared to the PCOS (P<0.001) and the level of expression of TNF-α in PCT compared to the PCOS (P<0.05). Significant decrease in the thickness of theca follicle layer in PCT compared to the PCOS (P<0.05). Conclusion: The investigation of apoptosis in ovary tissue showed a significant increase in apoptosis index in PCOS compared to PCT with simvastatin. The effects of simvastatin in PCOS may be due to the inhibitory trace on TNF-α and AMH.
Palavras-chave
Referências
Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Molecular and cellular endocrinology. 2011;335(1):30-41.
Benson S, Janssen O, Hahn S, Tan S, Dietz T, Mann K, et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain, behavior, and immunity. 2008;22(2):177-84.
Mannerås L, Cajander S, Holmäng A, Seleskovic Z, Lystig T, Lönn M, et al. A New Rat Model Exhibiting Both Ovarian and Metabolic Characteristics of Polycystic Ovary Syndrome. Endocrinology. 2007;148(8):3781–91.
Pizarro JG, Verdaguer E, Ancrenaz V, Junyent F, Sureda F, Pallàs M, et al. Resveratrol inhibits proliferation and promotes apoptosis of neuroblastoma cells: role of sirtuin 1. Neurochemical research. 2011;36(2):187-94.
McGrath K-C, McRobb L, Heather AK. Androgen therapy and atherosclerotic cardiovascular disease. Vascular health and risk management. 2008;4(1):11.
Shi D, Dyck MK, Uwiera RR, Russell JC, Proctor SD, Vine DF. A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome. Endocrinology. 2009;150(9):4425-36.
Park HJ, Lee HJ, Choi MS, Son DJ, Song HS, Song MJ, et al. JNK pathway is involved in the inhibition of inflammatory target gene expression and NF-kappaB activation by melittin. Journal of inflammation. 2008;5(1):1-13.
Matsuoka M, Pham Nt, Tsukamoto H. Differential effects of interleukin‐1α, tumor necrosis factor α, and transforming growth factor β1 on cell proliferation and collagen formation by cultured fat‐storing cells. Liver. 1989;9(2):71-8.
MO J-S, Matsukawa A, Ohkawara S, Yoshinaga M. Involvement of TNF α, IL-1β and IL-1 receptor antagonist in LPS-induced rabbit uveitis. Experimental eye research. 1998;66(5):547-57.
Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators of inflammation. 2010;2010.
Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002;143(3):1076-84.
Masse V, Ferrari P, Boucoiran I, Delotte J, Isnard V, Bongain A. Normal serum concentrations of anti-Müllerian hormone in a population of fertile women in their first trimester of pregnancy. Human reproduction. 2011;26(12):3431-6.
Sokalska A, Stanley SD, Villanueva JA, Ortega I, Duleba AJ. Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells. Biology of Reproduction. 2014;90(2):44, 1-6.
Stewart D, Dombroski B, Urbanek M, Ankener W, Ewens K, Wood J, et al. Fine mapping of genetic susceptibility to polycystic ovary syndrome on chromosome 19p13. 2 and tests for regulatory activity. The Journal of Clinical Endocrinology & Metabolism. 2006;91(10):4112-7.
Altieri DC. Statins' benefits begin to sprout. J Clin Invest. 2001;108(3):365–6.
Tamayo E, Alvarez F, Alonso Q, Bustamante R, Castrodeza J, Soria S, et al. Effects of simvastatin on systemic inflammatory responses after cardiopulmonary bypass. Journal of Cardiovascular Surgery. 2009;50(5):687.
Ortega I, Cress AB, Wong DH, Villanueva JA, Sokalska A, Moeller BC, et al. Simvastatin reduces steroidogenesis by inhibiting Cyp17a1 gene expression in rat ovarian theca-interstitial cells. Biology of reproduction. 2012;86(1):20, 1-9.
Ikeda K, Baba T, Morishita M, Honnma H, Endo T, Kiya T, et al. Long-term treatment with dehydroepiandrosterone may lead to follicular atresia through interaction with anti-Mullerian hormone. Journal of ovarian research. 2014;7(1):46.
Sparrow C, Burton C, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflammatory and anti-atherosclerotic activities independent of plasma cholesterol-lowering. Atherosclerosis. 2000;151(1):188.
Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Human Reproduction. 2007;22(9):2414-21.
Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction. 2006;131(1):1-9.
Chao K-C, Ho C-H, Shyong W-Y, Huang C-Y, Tsai S-C, Cheng H-Y, et al. Anti-Mullerian hormone serum level as a predictive marker of ovarian function in Taiwanese women. Journal of the Chinese Medical Association. 2012;75(2):70-4.
Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Human Reproduction. 2009;24(11):2917.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. The Journal of Clinical Endocrinology & Metabolism. 2006;91(11):4237-45.
Spanos N, Tziomalos K, Macut D, Koiou E, Kandaraki EA, Delkos D, et al. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss. Obesity facts. 2012;5(4):495-504.
Ergenoglu M, Yildirim N, Yildirim AGS, Yeniel O, Erbas O, Yavasoglu A, et al. Effects of resveratrol on ovarian morphology, plasma anti-mullerian hormone, IGF-1 levels, and oxidative stress parameters in a rat model of polycystic ovary syndrome. Reproductive Sciences. 2015;22(8):942-7.
Krysko DV, Berghe TV, Parthoens E, D'Herde K, Vandenabeele P. Methods for distinguishing apoptotic from necrotic cells and measuring their clearance. Methods in enzymology. 2008; 442:307-41.
This is an open-access article distributed under the terms of the Creative Commons Attribution License
Apontamentos
- Não há apontamentos.
Visitas